Vincenzo Catalano

7.0k total citations
124 papers, 5.1k citations indexed

About

Vincenzo Catalano is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Vincenzo Catalano has authored 124 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 27 papers in Surgery. Recurrent topics in Vincenzo Catalano's work include Colorectal Cancer Treatments and Studies (55 papers), Gastric Cancer Management and Outcomes (45 papers) and Cancer Treatment and Pharmacology (18 papers). Vincenzo Catalano is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Gastric Cancer Management and Outcomes (45 papers) and Cancer Treatment and Pharmacology (18 papers). Vincenzo Catalano collaborates with scholars based in Italy, United States and New Zealand. Vincenzo Catalano's co-authors include Francesco Graziano, Paolo Giordani, Stefano Cascinu, Anna Maria Baldelli, Roberto Labianca, Daniele Santini, Mauro Magnani, Giordano Beretta, Giuseppe Tonini and Annamaria Ruzzo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Vincenzo Catalano

121 papers receiving 5.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincenzo Catalano Italy	40	3.1k	1.6k	1.4k	1.2k	900	124	5.1k
Gennaro Galizia Italy	43	2.8k 0.9×	1.9k 1.2×	1.2k 0.8×	1.3k 1.1×	731 0.8×	140	5.2k
Jae Kyung Roh South Korea	30	4.2k 1.4×	1.8k 1.1×	1.1k 0.8×	1.2k 1.0×	1.3k 1.5×	156	5.9k
Filippo Pietrantonio Italy	37	2.9k 0.9×	1.5k 0.9×	1.1k 0.8×	1.1k 1.0×	1.2k 1.3×	298	5.0k
Michelle R. Mahoney United States	32	3.4k 1.1×	1.7k 1.0×	757 0.5×	1.2k 1.0×	1.3k 1.5×	71	4.8k
Arnaud Roth Switzerland	34	3.4k 1.1×	1.8k 1.1×	860 0.6×	1.3k 1.1×	1.4k 1.6×	115	5.1k
Mario Scartozzi Italy	44	3.7k 1.2×	2.1k 1.3×	1.7k 1.2×	834 0.7×	1000 1.1×	343	6.4k
Ferdinando De Vita Italy	43	3.4k 1.1×	2.2k 1.3×	2.0k 1.4×	1.2k 1.0×	540 0.6×	207	6.0k
Ilhan Celik Germany	15	2.8k 0.9×	1.6k 1.0×	749 0.5×	682 0.6×	911 1.0×	31	3.9k
Young Suk Park South Korea	41	4.0k 1.3×	2.3k 1.4×	1.3k 0.9×	1.9k 1.6×	738 0.8×	227	6.3k
Piercarlo Saletti Switzerland	29	4.3k 1.4×	2.1k 1.3×	1.0k 0.7×	941 0.8×	1.6k 1.8×	74	5.5k

Countries citing papers authored by Vincenzo Catalano

Since Specialization

Citations

This map shows the geographic impact of Vincenzo Catalano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincenzo Catalano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincenzo Catalano more than expected).

Fields of papers citing papers by Vincenzo Catalano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincenzo Catalano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincenzo Catalano. The network helps show where Vincenzo Catalano may publish in the future.

Co-authorship network of co-authors of Vincenzo Catalano

This figure shows the co-authorship network connecting the top 25 collaborators of Vincenzo Catalano. A scholar is included among the top collaborators of Vincenzo Catalano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincenzo Catalano. Vincenzo Catalano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruzzo, Annamaria, Francesco Graziano, Nicholas W. Fischer, et al.. (2024). Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy. The Oncologist. 30(3).

Natalucci, Valentina, Carlo Ferri Marini, Francesco Lucertini, et al.. (2021). Effects of a Home-Based Lifestyle Intervention Program on Cardiometabolic Health in Breast Cancer Survivors during the COVID-19 Lockdown. Journal of Clinical Medicine. 10(12). 2678–2678. 25 indexed citations

Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2017). Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Annals of Oncology. 28. vi3–vi3. 2 indexed citations

Fiorentini, Giammaria, Donatella Sarti, Luca Mulazzani, et al.. (2016). Hepatic arterial infusion of Polythylene Glycol drug-eluting beads for Primary liver cancer therapy. Annals of Oncology. 27. iv24–iv24. 2 indexed citations

Zaniboni, Alberto, Enrico Aitini, Sandro Barni, et al.. (2012). FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemotherapy and Pharmacology. 69(6). 1641–1645. 65 indexed citations

Catalano, Vincenzo, Renato Bisonni, Francesco Graziano, et al.. (2012). A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 16(3). 411–419. 28 indexed citations

Catalano, Vincenzo, Fotios Loupakis, Francesco Graziano, et al.. (2011). Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Annals of Oncology. 23(1). 135–141. 88 indexed citations

Loupakis, Fotios, Annamaria Ruzzo, Lisa Salvatore, et al.. (2011). Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 11(1). 247–247. 58 indexed citations

Catalano, Vincenzo, Fotios Loupakis, Francesco Graziano, et al.. (2009). Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer. 100(6). 881–887. 158 indexed citations

10.

Santini, Daniele, Bruno Vincenzi, Enrico Vasile, et al.. (2009). Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): Final results of phase II trial. Journal of Clinical Oncology. 27(15_suppl). e15510–e15510. 4 indexed citations

11.

Cascinu, Stefano, Roberto Labianca, Carlo Barone, et al.. (2007). Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI Journal of the National Cancer Institute. 99(8). 601–607. 71 indexed citations

12.

Ruzzo, Annamaria, Francesco Graziano, Francesca Pizzagalli, et al.. (2005). Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Annals of Oncology. 16(6). 887–892. 59 indexed citations

13.

Scartozzi, Mario, Gennaro Galizia, Francesco Graziano, et al.. (2005). Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer. 92(6). 1051–1054. 14 indexed citations

14.

Piga, Andrea, Rosaria Gesuita, Vincenzo Catalano, et al.. (2005). Identification of Clinical Prognostic Factors in Patients with Unknown Primary Tumors Treated with a Platinum-Based Combination. Oncology. 69(2). 135–144. 8 indexed citations

15.

Santini, Daniele, Francesco Graziano, Vincenzo Catalano, et al.. (2004). Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Journal of Clinical Oncology. 22(14_suppl). 4237–4237. 2 indexed citations

16.

Cascinu, Stefano, Roberto Labianca, Vincenzo Catalano, et al.. (2003). Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology. 14(2). 205–208. 22 indexed citations

17.

Graziano, Francesco, Daniele Santini, E. Testa, et al.. (2003). A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. British Journal of Cancer. 89(8). 1428–1432. 17 indexed citations

18.

Graziano, Francesco, Renato Bisonni, Vincenzo Catalano, et al.. (2002). Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. British Journal of Cancer. 86(12). 1854–1857. 77 indexed citations

19.

Cascinu, Stefano, Vincenzo Catalano, C. Aschele, et al.. (2000). Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil—leucovorin combination. Annals of Oncology. 11(8). 1053–1056. 20 indexed citations

20.

Graziano, Francesco, Vincenzo Catalano, Anna Maria Baldelli, et al.. (2000). A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Annals of Oncology. 11(10). 1263–1266. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact